A Description of Clinician Reported Diagnosis of Type 2 Diabetes and Other Non-Type 1 Diabetes Included in a Large International Multicentered Pediatric Diabetes Registry (SWEET) by Pacaud, D et al.
OR I G I N A L A R T I C L E
A description of clinician reported diagnosis of type 2 diabetes
and other non-type 1 diabetes included in a large international
multicentered pediatric diabetes registry (SWEET)
Danièle Pacaud MD, FRCPC1 | Anke Schwandt MSc2,3 | Carine de Beaufort MD, PhD4,5 |
Kristina Casteels MD, PhD6,7 | Jacques Beltrand MD, PhD8,9 |
Niels H. Birkebaek MD, PhD10 | Myrna Campagnoli MD11 | Natasa Bratina MD, PhD12 |
Catarina Limbert MD13 | Stephen MP O’Riordan MD14 | Rogério Ribeiro MD, PhD15 |
Andriani Gerasimidi-Vazeou MD16 | Lenka Petruzelkova MD17 |
Rasa Verkauskiene MD, PhD18 | Iveta Dzivite Krisane MD, PhD19 | the SWEET Study Group
1Alberta Children’s Hospital Research Institute,
University of Calgary, Calgary, Canada
2Institute of Epidemiology and Medical Biometry,
ZIBMT, University of Ulm, Ulm, Germany
3German Center for Diabetes Research (DZD),
Munich-Neuherberg, Germany
4Diabetes and Endocrinology Care Clinique
Pédiatrique (DECCP), Centre Hospitalier de
Luxembourg, Luxembourg, Luxembourg
5Division of Paediatric Endocrinology,
University Hospital Brussels, Brussels, Belgium
6Department of Pediatrics, University
Hospitals Leuven, Leuven, Belgium
7Department of Development and
Regeneration, KU Leuven, Leuven, Belgium
8Service d’endocrinologie gynécologie et
diabétologie pédiatrique, Hôpital Universitaire
Necker Enfants Malades, Assistance publique
Hôpitaux de Paris, Paris, France
9Faculté de médecine Paris Descartes,
Université Sorbonne Paris cité, Paris, France
10Department of Pediatrics, Aarhus University
Hospital, Aarhus, Denmark
11Centro de Diabetes de Curitiba, Paraná, Brazil
12Departement of endocrinology, diabetes and
metabolic diseases, University Childrens hospital,
University medical centre, Ljubljana, Slovenia
13Hospital Dona Estefânia, Unit of Pediatric
Endocrinology and Diabetes, Lisbon, Portugal
14Paediatric Endocrinology, Department of
Paediatrics & Child Health, Cork University
Hospital, Cork, Ireland
15Associação Protectora dos Diabéticos de
Portugal (APDP), Lisbon, Portugal
16Department of Pediatrics, P & A Kyriakou
Children’s Hospital, Diabetes Centre, Athens,
Greece
Background: Although type 1 diabetes (T1D) remains the most frequent form of diabetes in
individuals aged less than 20 years at onset, other forms of diabetes are being increasingly
recognized.
Objectives: To describe the population of children with other forms of diabetes (non-type 1)
included in the multinational SWEET (Better control in Pediatric and Adolescent diabeteS:
Working to crEate CEnTers of Reference) database for children with diabetes.
Methods: Cases entered in the SWEET database are identiﬁed by their physician as T1D, type
2 diabetes (T2D) and other types of diabetes according to the ISPAD classiﬁcation. Etiologic
subgroups are provided for other types of diabetes. Descriptive analyses were tabulated for
age at onset, gender, daily insulin doses, and hemoglobin A1c (A1C) for each type and subtype
of diabetes and when possible, values were compared.
Results: Of the 27104 patients included in this report, 95.5% have T1D, 1.3% T2D, and 3.2%
other forms of diabetes. The two most frequent etiologies for other forms of diabetes were
maturity onset diabetes of the young (MODY) (n = 351) and cystic ﬁbrosis-related diabetes
(CFRD) (n = 193). The cause was unknown or unreported in 10% of other forms of diabetes.
Compared with T1D, children with T2D and CFRD were diagnosed at an older age, took less
insulin and had lower A1C (all P < .0001).
Conclusion: In centers included in SWEET, forms of diabetes other than type 1 remain rare and
at times difﬁcult to characterize. Sharing clinical information and outcome between SWEET cen-
ters on those rare forms of diabetes has the potential to improve management and outcome.
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1 | INTRODUCTION
Although type 1 diabetes (T1D) remains the most frequent form of
diabetes in individuals aged less than 20 years at onset, other forms
of diabetes including type 2 diabetes (T2D) and monogenic forms of
diabetes are being increasingly recognized.1 Reports from different
sources suggest that between 2% and 15% of children affected by
diabetes will have non-T1D.2,3 Although T2D is being recognized
more frequently and could represent up to 11% of children affected
by diabetes in the USA,4 it remains a fairly rare form of diabetes in
other countries. Prevalence of T2D is often reported as being similar
or even lower than monogenic forms of diabetes.5
The management of diabetes in children is changing rapidly and
more options are becoming available. Management of T1D is an inten-
sive process requiring signiﬁcant education, time, and resources. How-
ever, this management approach may not be required in other forms
of diabetes such as in glucokinase (GCK) gene mutations (MODY 2)
where use of insulin exposes the child to unnecessary daily injections
and risks of hypoglycemia.6 Making the correct diagnosis of diabetes
type and subtype is important to offer the most appropriate treat-
ment, to conduct targeted screening of complications and associated
conditions, and for genetic counseling of the families.3
SWEET comprises a large multinational consortium of pediatric
diabetes clinics collecting basic diabetes-related information on their
patients in a single, standardized database. This provides a unique
opportunity to evaluate the frequency, presentation, treatment, and
follow up of forms of clinician reported diagnosis of diabetes other
than type 1. Hence, the aim of this manuscript is to describe the pop-
ulation of children with other forms of diabetes (non-type 1) included
in the multinational SWEET database for children with diabetes.
2 | METHODS
SWEET is the acronym for “Better control in Pediatric and Adolescent
diabeteS: Working to crEate CEnTers of Reference,” a multinational
initiative to improve diabetes care and outcomes in youth with diabe-
tes. Before being allowed to join, each center has to meet speciﬁc
entry criteria demonstrating their pediatric diabetes expertise and
compliance with the International Society for Pediatric and Adoles-
cent Diabetes clinical practice guidelines.7 For the data collection, the
SWEET project incorporates data from heterogeneous sources: cen-
ters may use DPV (“Diabetes-Patienten-Verlaufskodumentation,”
https://sweet.zibmt.uni-ulm.de/software.php), DIAMAX, download
data of existing registries or use own local databases to collect data.
Since 2006, twice per year, prospective data extracted from clinical
visit documentation are transferred from individual centers to the
SWEET data management unit at the Institute of Epidemiology and
Medical Biometry, University of Ulm, Ulm, Germany. Data are
examined for inconsistency or improbability and reported back to
centers for veriﬁcation. Moreover, reports are generated comparing
outcomes between participating centers.
Individual centers obtained local ethics approval. Individual
informed consent from patient or parents in the case of minors were
obtained when required by local regulations.
As of February 2016, SWEET included 48 participating centers
(37 from Europe) with 281906 visits in 28713 patients. After exclud-
ing patients with missing gender, age, diabetes duration or diabetes
type, diagnosed after the age of 20 y, and patients with glucose intol-
erance not yet diagnosed with diabetes, 27 104 patients remained for
analysis (Figure 1). For each patient, the data from the latest visit
available was used for categorical variables including diabetes type
and subtype. Data from continuous variables were aggregated from
visits of the last 2 years of observation so that individual patients are
represented only once.
This is a multicentered cross-sectional observational descriptive
study. Type and subtypes of diabetes are determined by their treating
physician and reported in the database according to the ISPAD classi-
ﬁcation table8 (see our Table 1). At this time, the SWEET database
does not include information on the method used to make the diag-
nosis or on speciﬁc mutations identiﬁed. Types of diabetes reported
are type 1, type 2, gestational diabetes or other forms of diabetes. If
a child was diagnosed with diabetes before the age of 6 months, but
no speciﬁc genetic diagnosis was mentioned, this case was included
under genetic defect of β-cell function. For descriptive purposes,
reported diabetes subtypes were regrouped into genetic defect of
β-cell function (MODY and neonatal diabetes), genetic defects of
insulin action, cystic ﬁbrosis-related diabetes (CFRD), other disease of
the exocrine pancreas (excluding CFRD), endocrinopathies, drug or
SWEET database
28713
Final sample for analysis
27104
Excluded due to missing 
age, gender, diabetes 
duration or age at onset 
greater than 20 yrs
1027
excluded due to diagnosis 
of glucose intolerence
582
FIGURE 1 Sample description.
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chemically induced diabetes, infections, uncommon forms of
immune-mediated diabetes and other genetic syndromes sometimes
associated with diabetes.
The main clinical information available for this paper include age
at onset (y), gender, type, and subtype of diabetes and for each visit
height (cm), weight (kg), body mass index (BMI, kg/m2), BMI z-
scores [according to the World Health Organization (WHO) growth
charts],9 hemoglobin A1c (A1C, %), use of insulin (yes/no), total daily
insulin dose (units per kg) and use of oral antihyperglycemic agents
(yes/no). In order to adjust for differences between laboratories for
A1C measurements, multiple of the mean (MOM) method10 was
used to mathematically standardize A1C values to the reference
range of the Diabetes Control and Complications Trial (DCCT,
4.0%–6.0%; 20–42 mmol/mol).
In preparation for this special supplement on SWEET, we asked
all participating centers to complete an online survey including ques-
tions on where would children and adolescents with cystic ﬁbrosis-
related diabetes, T2D, and adolescents with diabetes in pregnancy be
followed. Of 48 centers 32 completed the survey (response
rate 67%).







Genetic defects of β-cell function Drug- or chemical-induced
Chromosome 12, HNF-1α (MODY 3) 66 Vacor
Chromosome 7, glucokinase (MODY 2) 188 Pentamidine
Chromosome 20, HNF-4α (MODY 1) 7 Nicotinic acid
Chromosome 13, insulin promoter factor- (IPF-1; MODY 4) 4 Glucocorticoids 17
Chromosome 17, HNF-1β (MODY 5) 18 Thyroid hormone
Chromosome 2, NeuroD1 (MODY 6) 1 Diazoxide 1
Mitochondrial DNA mutation 5 β-adrenergic agonists
Chromosome 7, KCNJ11 (Kir6.2) and other forms
of neonatal diabetes
54 Thiazide
Others 62 Dilantin 2
α-Interferon
Others 29
Genetic defects in insulin action Infections





Diseases of the exocrine pancreas Uncommon forms of immune-mediated
diabetes
Pancreatitis 4 “Stiff-man” syndrome
Trauma/pancreatectomy 3 Anti-insulin receptor antibodies
Neoplasia 8 Polyendocrine autoimmune
Cystic ﬁbrosis 193 deﬁciencies APS I and II
Haemochromatosis 1 Others 5
Fibrocalculous pancreatopathy 2
Others 41
Endocrinopathies Other genetic syndromes sometimes
associated with diabetes
Acromegaly Trisomy 21 syndrome 18
Cushing’s syndrome Klinefelter syndrome 2
Glucagonoma Turner syndrome 1
Phaeochromocytoma Wolfram syndrome 12
Hyperthyroidism Friedreich’s ataxia 1
Somatostatinoma Huntington’s chorea
Aldosteronoma Laurence-Moon-Biedl syndrome




26 PACAUD ET AL.
2.1 | Statistical analysis
Results are presented as median with lower and upper quartile for
continuous variables or as number and percentage for binary or cate-
gorical variables. Wilcoxon test was used to compare continuous vari-
ables between groups and chi-square test for categorical variables.
Linear regression models compared the metabolic control (A1C)
between T1D, T2D, and CFRD adjusted for age, diabetes duration,
and gender were presented as adjusted mean and standard error (SE).
A Spearman correlation was used to assess the association between
center size and percentage of rare diabetes or T2D from each center.
All analyses were done using Statistical Analysis Software 9.4
(SAS, SAS Institute Inc., Cary, NC, USA). Two-sided P-value < .05 was
considered as signiﬁcant.
3 | RESULTS
As shown in Figure 2, of the 27 104 patients included in this report,
25 889 (95.5%) had T1D, 347 (1.3%) T2D, 2 (<0.01%) gestational dia-
betes, and 866 (3.2%) other forms of diabetes. For those identiﬁed
by their physician as having another form of diabetes, a speciﬁc sub-
class was provided in 90% and unknown or unreported in 10.0%. The
distribution of other forms of diabetes can be seen in Figure 2. The
most frequent groups were MODY 2 (n = 188) and CFRD (n = 193).
The frequency of the speciﬁc etiologies of diabetes can be seen
in Table 1. The clinical characteristics of these different subgroups
can be found in Table 2. Of note, a total of 351 children were cate-
gorized as MODY (total of MODY 1, 2, 3,4,5,6). Although no
statistical analysis was performed due to the small group size, it
appears that children with MODY 2 are younger at diagnosis. Only
7% were on insulin with a median insulin dose of 0.2 (0.1; 0.5) U/kg/
d. However, in this dataset, the reported A1C levels appear similar in
all MODY groups. In addition, Table 2 presents the characteristics of
children with diabetes because of monogenic forms of neonatal dia-
betes, disease of the exocrine pancreas (excluding CFRD), drug or
chemical or associated with a genetic syndrome.
In unadjusted comparison between children with T1D and with
T2D, children and adolescents with T2D were older, more frequently
girls, and older at diagnosis (Table 3). They also have a shorter duration
of diabetes, lower A1C, lower daily insulin doses per kilogram, and higher
BMI z-scores. In contrast, children with T2D and CFRD had similar dura-
tion of diabetes, yet shorter than for those with T1D. T2D and CFRD
also had similar female predominance in contrast with T1D that showed
no gender difference. Children with CFRD had the lowest BMI z-score.
When adjusting for age, gender, and duration of diabetes, A1C remained
different between groups (T1D 8.21 ± 0.01% or 66 ± 0.1 mmol/mol vs.
T2D 7.68 ± 0.10% or 61 ± 1 mmol/mol, p<0.0001) and children with
CFRD were found to have the lowest A1C compared to both T1D
(CFRD 6.32 ± 0.12% or 45 ± 1 mmol/mol vs. T1D 8.21 ± 0.01% or 66 ±
0.1 mmol/mol , p<0.0001) and T2D (CFRD 6.35 ± 0.15% or 46 ± 2
mmol/mol vs. T2D 7.75 ± 0.12% or 62 ± 1 mmol/mol , p<0.0001).
Of the 48 diabetes clinics participating, 7 reported on more than
1000 patients, 33 between 150 to 1000 patients, and 8 on less than
150 patients since the beginning of their contribution to SWEET. The
proportion of T2D ranged from 0% to 8.3%. There was a weak correla-
tion between center size and the percentage of patients with T2D per
center (Spearman Rho 0.45, P = .001). The proportion of other forms
FIGURE 2 Distribution of types and subtypes of diabetes.
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of diabetes ranged from 0% to 9.6%. There is also a weak correlation
between center size and the percentage of patients with other forms
included in their SWEET cohort (Spearman Rho 0.38, P = .007).
In preparation for this manuscript, we asked each center where
would patients with T2D, cystic ﬁbrosis, and diabetes in pregnancy in
youth (gestational or pre-existing) be followed (Table 4). Interestingly
most centers indicated that for both, T2D and CFRD, they would be
involved in the follow up either within their pediatric diabetes clinic
or by the pediatric diabetes team within a joint clinic. For diabetes in
pregnancy (either gestational diabetes or pre-existing T1D) answers
were more variable with over half of the centers transferring care to
a diabetes pregnancy clinic.
4 | DISCUSSION
This report provides a clinical description of other forms of diabetes
encountered in the SWEET database, reﬂecting real world clinical
practice of a large, multinational consortium of centers caring for chil-
dren with diabetes. Both observed frequency and clinical characteris-
tics of non-T1D in this database are similar to published literature.
The frequency of non-T1D (<5%) remains a small proportion of
children followed by participating clinics. Although we cannot meas-
ure prevalence or incidence through the SWEET database, it is inter-
esting that the distribution of the different forms of diabetes within
the database is in line with most reports of prevalence or incidence
for T2D and other forms of diabetes, which are between 2% and
15%.2,3 When using similar clinical criteria applied by expert clini-
cians, the proportion of children with T2D has been reported to be as
high as 11% of all children with diabetes in the USA,4 whereas it
remains a much lower proportion in Europe.2,5,11,12 Contrary to North
American reports,4,13 the frequency of T2D is usually similar to that
of MODY in European countries.11,14 At least two European centers
have published higher frequency of MODY than T2D.2,5 The differen-
tial diagnosis between MODY and T2D or T1D remains clinically dif-
ﬁcult and requires genetic testing.15 Examples from the literature




























Gender male/female (%) 54/46 35/65 50/50 41/59 42/58 40/60 58/42
Age at diagnosis (y) 7.9 (4.5;11.8) 11.7 (8.5; 14.0) 11.0 (4.9; 13.5) 0.2 (0.0; 0.5) 14.1 (10.8; 16.4) 12.1 (9.1;15.1) 7.3 (2.4; 11.0)
Diabetes duration (y) 3.9 (2.0; 6.6) 5.1 (2.5; 7.1) 1.7 (0.6; 4.4) 5.2 ( 2.2; 11.0) 5.0 (1.9; 10.4) 2.7 (0.5; 4.8) 8.3 (2.8; 11.5)
Documented insulin
treatment (%)
7 38 11 39 56 52 77
Daily insulin dose (U/kg) 0.2 (0.1; 0.5) 0.6 (0.3; 0.8) 0.7 (0.6; 0,9) 0.7 (0.5; 0.8) 0.7 (0.5; 1.0) 0.8 (0.4;1.2) 1.0 (0.7; 1.2)
Oral antihyperglycemic
agents (%)
2 15 18 17 5 8 9
A1C (%) 6.2 (6.0; 6.4) 6.7 (5.9; 7.6) 6.2 (5.7; 6.7) 6.6 (5.7; 7.4) 6.6 (5.6; 7.4) 6.6 (6.2; 8.3) 7.2 (6.5; 8.2)
A1C (mmol/mol) 44 (42;46) 50 (41;60) 44 (39;50) 49 (39;57) 49 (38;57) 49 (44;67) 55 (48;66)
BMI z-score 0.2 (−0.6; 1.0) 0.5 (−0.3; 1.4) 0.4 (0.0; 1.6) 0.1 (−0.8; 1.0) 0.2 (−0.6; 0.8) 0.48 (−0.2; 2.2) 0.7 (−0.2; 1.8)
MODY, maturity onset diabetes of the young.
1Data presented as median (lower quartile; upper quartile) or percentage.
2Owing to small group size, no statistical comparison is presented.
3Excludes cystic ﬁbrosis-related diabetes.
TABLE 3 Comparison between type 1 diabetes, type 2 diabetes, and CFRD1
T1D (n = 25 889) T2D (n = 347) CFRD (n = 193)
Gender male/female (%) 52/48 40/602 44/564
Age at diagnosis (years) 7.8 (4.3; 11.2) 13.8 (12.0;15.5)2 12.9 (10.8; 14.8)2,3
Diabetes duration (years) 5.2 (2.3; 9.1) 2.3 (1.1; 4.5)2 2.5 (1.2; 4.8)2
Documented insulin treatment (%) 272 572,3
Daily insulin dose (U/kg) 0.9 (0.7; 1.1) 0.7 (0.3; 0.9)2 0.4 (0.1; 0.8)2,3
A1C (%) 7.9 (7.1; 8.9) 7.1 (6.0; 8.9)2 6.0 (5.6; 6.7)2,3
A1C (mmol/mol) 63 (54; 74) 54 (42; 74)2 42 (38; 50)2,3
BMI z-score 0.5 (−0.2; 1.2) 2.5 (1.8; 3.2)2 −0.5 (−1.0 0.1)2,3
CFRD, cystic ﬁbrosis related diabetes; T1D, type 1 diabetes; T2D, type 2 diabetes.
1Data presented as median (lower quartile; upper quartile) or percentages.
2Indicates a statistical difference with T1D with a P-value < .01.
3Indicates a statistical difference with T2D with a P-value ≤ .01.
4Indicates a statistical difference with T1D with a P-value = .03.
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suggest that centers with higher frequency of MODY as compared
with T2D had easy access to genetic testing resulting in more sys-
tematic testing of children with negative antibody regardless of clini-
cal characteristics.2,5,13 Because the majority of SWEET centers are
located in Europe, it is not surprising that the frequencies seen here
are similar to those reports. As SWEET continues to grow and more
centers from outside Europe join, it will be interesting to monitor if
these proportions change.
Use of the ISPAD classiﬁcation of diabetes8 to document diabetes
type is a sound starting point. However, as seen within this project, in
some cases it remains difﬁcult to assign a diabetes subtype. Some cen-
ters may not have access to genetic testing. Other children may have
been tested but found to be negative for the known genetic causes. In
other cases, there is no clear category to choose from. For example,
an infant with pancreatic agenesis with negative genetic testing could
be classiﬁed under monogenic forms of diabetes (as this remains most
likely) or under exocrine pancreatic disease. Some diagnoses may
overlap between categories such as diabetes secondary to pancreatitis
caused by chemotherapy, which could be entered under pancreatitis
or under drug or chemical-induced diabetes. New speciﬁc drugs caus-
ing diabetes, such as atypical psychotic agents and calcineurin inhibi-
tors, have emerged since the start of SWEET and are not listed in the
current list. When dealing with large databases, it is impractical to ver-
ify each case for clariﬁcation and consistency. Although, the list of
other forms of diabetes designed for SWEET in 2006 was carefully
thought out and used the published ISPAD classiﬁcation available at
the time, new etiologic diagnoses have become available over the last
decade. This suggests that the current SWEET classiﬁcation should be
revised at regular intervals to ensure inclusion of new diagnostic enti-
ties. Many of the other forms of diabetes require genetic testing for
conﬁrmation of the diagnosis. Being aware of the high number of chil-
dren with unclassiﬁed subtype and unclassiﬁed MODY, collaboration
with the ISPAD rare forms of diabetes center in Exeter (http://www.
diabetesgenes.org/content/information-known-types-rare-diabetes)
and EURO-WABB project (http://web.ispad.org/resource-type/ispad-
rare-diabetes) will also allow SWEET centers without genetic facilities
to classify their cases appropriately. Lastly, individual centers also
need to be attentive and update the diagnosis for each case when
more information becomes available over time.
Another difﬁculty that arises with this classiﬁcation for research
is the wide variety of pathologies that are included in the same
subgroup. For example, analyzing outcome of genetic defect of β-cell
function as a single group does not provide us with a clear clinical
picture as it includes neonatal diabetes which often requires early
and lifelong treatment, with MODY 2 which has a benign course and
other MODY which may be associated with early complications. The
same issue is present within most of the other larger categories of
this classiﬁcation. Hence, when presenting clinical outcome, these eti-
ologic classiﬁcation categories need to be subdivided in order to pro-
vide more accurate and pertinent information.
The proportion of children with MODY 2 being on insulin is
worth discussing. A previous report from the DVP initiative had
observed a similar rate of insulin use (8%) in pediatric patients with
MODY 2.12 This form of diabetes is associated with mild hyperglyce-
mia often present from birth16 and slight increase in A1C with slight
deterioration with age similar to what is seen in individuals without
diabetes.17,18 Pharmaceutical treatment does not normalize glyce-
mia.19 Further, this condition is rarely associated with the typical
long-term complications of diabetes even in the absence of treat-
ment.6 Between the monetary cost, personal burden associated with
daily insulin injections and potential risk of hypoglycemia, it seems
surprising to have 7% of children with MODY 2 on this treatment.
Nevertheless, it was reassuring to see the total daily dose being mini-
mal, probably resulting in minimal risk of hypoglycemia. Further
inquiry of those cases could help us understand the reasons behind
the ongoing use of insulin.
In the survey, most centers expected to be following the majority
of children with T2D within their catchment area. Without population
base data, it is difﬁcult to ascertain the validity of this information.
However, both Amed et al.13 and Neu et al.11 found that over 90%
of the children with T2D and rare forms of diabetes in their study
were being followed by pediatric diabetes specialists or pediatricians.
Nevertheless, it is possible that children with T2D are under-
represented in this database because they are followed elsewhere
unbeknownst to the pediatric diabetes clinics in SWEET, or because
they remain undiagnosed.20 The lower frequency could also be
related to lower frequency of childhood obesity.1 Another point to
consider for children with T2D is that most pediatric diabetes pro-
grams are built around the clinical management of children with T1D.
Even if some aspects of diabetes care overlap, the needs for manag-
ing T2D may be different from those for managing T1D. For example,
the management of T2D requires intensive lifestyle changes often








Joint clinic for CFRD
and diabetes3
Type 2 diabetes 31 (97) 0 (0) 1 (3)
CFRD 3 (9) 3 (9) 1 (3) 23 (72)
Known patient with type 1 diabetes who becomes pregnant 9 (28) 15 (47) 7 (22)
New adolescent patient with gestational diabetes 8 (25) 17 (53) 7 (22)
CRDR, cystic ﬁbrosis-related diabetes.
1Data are presented as number (percentages) of respondents.
2Within each question this was given as obesity clinic for type 2 diabetes, CFRD clinic for CFRD and diabetes in pregnancy clinic for the two questions
on pregnancy.
3The option of a joint clinic was offered for CFRD only.
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coupled with signiﬁcant psychosocial interventions21 that may be
better served in a pediatric obesity clinic with collaboration with
pediatric diabetes specialists. However, pediatric obesity clinics are
not always available and the pediatric diabetes clinic then needs to
adapt its management for those children. It remains to be proven
which type of clinic would serve this population best. The SWEET
collaboration offers an avenue to discuss these adaptations to meet
the clinical needs of T2D.
The group of children with CFRD in the SWEET database was
similar to the literature in terms of age of onset, weight and use of
insulin.22,23 Despite clear recommendation to initiate insulin early for
better overall outcome,24 there is often resistance to initiate this
treatment from the families and care givers resulting in one in ﬁve
children with CFRD not being on insulin.25 When organizing diabetes
care for children with CFRD, one must consider amongst other issues,
a dietary approach focused on high energy demands24 and infection
control measures.26 Close collaboration with the cystic ﬁbrosis clinic
is required. Accordingly, 23 out of 32 clinics in the survey stated
doing joint follow-up with cystic ﬁbrosis teams for these patients,
which is a higher proportion than in the UK.27
When considering the other causes of diabetes in children, most
pediatric diabetologists are expected to be involved in the care of a
few individuals with special rare forms of diabetes throughout their
career. The weak correlation between center size and the percentage
of other forms of diabetes in each participating center can be
explained in part by the numbers (ie, by random effect, larger centers
will be more likely to see rare forms). It could also be explained by a
referral bias by which unusual forms of diseases are more likely to be
sent to larger, more specialized clinics. Despite this correlation, each
center remained with very few cases of each speciﬁc etiology. Being
able to combine these cases in the SWEET database allows reporting
on a signiﬁcant number of patients with similar rare etiology that
could not be gathered otherwise. Beyond this publication, the
SWEET structure allows for better descriptions through internal
reports and case discussion at the annual meeting. Moreover, discus-
sion of organization of care through the peer review process may
help pediatric diabetes specialists to provide a more targeted
approach to these rare forms of diabetes.
This report has several limitations. First, this database is not pop-
ulation based. Therefore, no prevalence or incidence rates can be
deduced. Further, it is based on reported coding according to physi-
cian’s opinion. There is no systematic collection of information on ini-
tial diagnosis, laboratory or genetic testing to support the diagnosis.
Within this database, it is not possible to distinguish between sus-
pected or proven cases and, for those labeled as undetermined,
between those not investigated versus those thoroughly investigated
but without a speciﬁc diagnosis. Coding may not be consistent
throughout centers or even within centers. However, the size of the
population reported is unique and allows overcoming some of the
limits listed above.
In conclusion, forms of diabetes other than type 1 in the SWEET
dataset remain rare and at times difﬁcult to characterize. Because
each center has only a few cases of rare forms of diabetes, the
SWEET collaboration allows pediatric diabetes centers to share their
experiences resulting in increased awareness, knowledge, and
improve patient care. As our knowledge evolves, it will be important
to continue monitoring of the frequency and clinical outcomes of the
different rare forms of diabetes in this database.
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